Literature DB >> 18287137

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.

Tilmann Bochtler1, Ute Hegenbart, Christiane Heiss, Axel Benner, Friedrich Cremer, Martin Volkmann, Jochen Ludwig, Jolanta B Perz, Anthony D Ho, Hartmut Goldschmidt, Stefan O Schonland.   

Abstract

We evaluated the Serum Free Light Chain (FLC) test in a series of 133 untreated patients with systemic AL amyloidosis. The FLC test detected the monoclonal gammopathy in 87% compared with 92% for immunofixation of serum and urine in combination. However, both tests proved complementary. The FLC test was also a valuable tool in patients with advanced renal failure in spite of uninvolved light chain retention. Higher FLC levels were associated with higher bone marrow plasmocytosis, poorer Karnofsky index and heart involvement, and therefore reflected disease severity.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18287137     DOI： 10.3324/haematol.11687

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  16 in total

1.  [Systemic amyloidoses].

Authors:  S Schönland; N Blank; A V Kristen; J Beimler; T Ganten; U Hegenbart
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

2.  Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.

Authors:  Shaji Kumar; Angela Dispenzieri; Jerry A Katzmann; Dirk R Larson; Colin L Colby; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Nelson Leung; Steve R Zeldenrust; Marina Ramirez-Alvarado; Raynell J Clark; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  Blood       Date:  2010-08-26       Impact factor: 22.113

3.  Screening panels for monoclonal gammopathies: time to change.

Authors:  Jerry A Katzmann
Journal:  Clin Biochem Rev       Date:  2009-08

4.  A case of primary (AL) amyloidosis with predominantly vascular amyloid deposition in the kidney.

Authors:  Yoichi Murakami; Soken Hattori; Fumiko Sugiyama; Kazuyuki Yoshikawa; Takeshi Sugiura; Hideki Matsushima
Journal:  CEN Case Rep       Date:  2014-12-02

5.  Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.

Authors:  Pankaj Yadav; Maximilian Merz; Elias K Mai; Asta Försti; Anna Jauch; Hartmut Goldschmidt; Kari Hemminki
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941

Review 6.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

7.  Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.

Authors:  Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Steven R Zeldenrust; Tow Tan; Shirshendu Sinha; Nelson Leung; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  Am J Hematol       Date:  2011-02-15       Impact factor: 10.047

Review 8.  [Current diagnostic and therapy of light chain amyloidosis].

Authors:  S O Schönland; T Bochtler; A V Kristen; A D Ho; U Hegenbart
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

9.  Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease.

Authors:  Colin A Hutchison; Stephen Harding; Pete Hewins; Graham P Mead; John Townsend; Arthur R Bradwell; Paul Cockwell
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

10.  Screening panels for detection of monoclonal gammopathies.

Authors:  Jerry A Katzmann; Robert A Kyle; Joanne Benson; Dirk R Larson; Melissa R Snyder; John A Lust; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Clin Chem       Date:  2009-06-11       Impact factor: 8.327
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.